SUMO1在非小细胞肺癌中的表达及其临床意义

Clinicopathologic features and prognostic implications of small ubiquitin- related modifier 1 expression in non- small cell lung cancer

目的检测非小细胞肺癌(NSCLC)患者肺癌标本中泛素类似蛋白SUMO1的表达并分析其与癌症分型、临床分期以及患者的生存预后之间的关系。方法收集163例非小细胞肺癌患者手术切除的肺癌组织和邻近癌旁组织,通过免疫组织化学染色检测SUMO1的蛋白表达水平,统计分析SUMO1表达水平与病人临床病理参数的关系。使用Kaplan-Meier生存分析和Cox比例风险模型来评估SUMO1表达对病人生存的影响。结果结果显示SUMO1在74.23%的癌症患者的病变组织中高水平表达,相应的癌旁组织没有强的染色。临床病理参数的相关性分析表明,SUMO1表达与肿瘤分化程度显著相关(P=0.0038),与p TNM分期相关(P=0.0203),与淋巴转移相关(P<0.0001)。SUMO1过度表达的NSCLC患者存活时间显著缩短(P<0.0001)。多变量分析表明,SUMO1表达可能是非小细胞肺癌患者预后的独立因素(危险比[HR],1.731;P=0.005)。结论研究结果表明,SUMO1表达的可作为非小细胞肺癌预后的生物标志物。

Objective The increased expression of small ubiquitin- related modifier 1（ SUMO1）,a member of SUMO family,has been observed in several human malignancies including non- small cell lung cancer（ NSCLC）. However,the clinic relevance of SUMO1 expression in NSCLC remains unknown. Methods Lung cancer tissues and adjacent non- tumor tissues were collected from 163 patients with resected NSCLC. The SUMO1 expression level was detected by immunohistochemical staining. The association of SUMO1 expression with clinicopathological parameters,including the Ki- 67 labeling index（ LI）,was also evaluated. Kaplan- Meier survival analysis and Cox proportional hazards models were used to estimate the effect of SUMO1 expression on survival. Results Data showed that SUMO1 was highly expressed in 74. 23% cancer lesions and no strong staining was detected in corresponding adjacent non- cancerous tissues. Out of all the clinicopathological factors analyzed,SUMO1 expression was significantly correlated with the grade of tumor differentiation（ P = 0. 0038）,p TNM stage（ P = 0. 0203）,lymphatic metastasis（ P〈0. 0001） and high Ki- 67 LI（ P〈0. 0001）. SUMO1 overexpression NSCLC patients had a significantly shorter survival time（ P〈0. 0001,Log- rank test） and the prognostic significance of SUMO1 expression was apparent in adenocarcinoma patients（ P = 0. 03）,squamous cell carcinoma（ P = 0. 0056） and adenosquamous carcinoma（ P =0. 0004）. Multivariate analysis indicated that SUMO1 expression may be an independent prognostic fact in NSCLC（ hazard ratio [HR],1. 731; P =0. 005）. Conclusion Our results indicate that SUMO1 expression is of clinical significance and can serve as a prognostic biomarker in NSCLC.